S&P 500 Industrials Sector SEC Filings — June 04, 2026

04-06-2026

Atlantic Union Bankshares Corporation announced via an 8-K filing on June 4, 2026, that it will participate in a fireside chat at the Morgan Stanley US Financials Conference on June 10, 2026, at 4:00 p.m. EDT. The event will be accessible virtually. The filing is a Regulation FD disclosure and does not contain any financial results or material operational changes.

• · The press release was issued on June 4, 2026, and is attached as Exhibit 99.1.
• · The conference event is scheduled for Wednesday, June 10, 2026, at 4:00 p.m. EDT.
• · The filing is furnished under Item 7.01 and is not deemed filed for Section 18 of the Exchange Act.

04-06-2026

Syndax Pharmaceuticals announced a private placement of $250.0 million in 2.25% Convertible Senior Notes due 2031, expected to close on June 10, 2026, with net proceeds of approximately $243 million for general corporate purposes. The notes carry a 2.25% interest rate, mature on June 15, 2031, and have an initial conversion price of $24.76 per share, representing a 35% premium over the stock's last reported sale price on June 3, 2026. The company is a commercial-stage biopharmaceutical firm with FDA-approved products Revuforj and Niktimvo, but the filing does not disclose any negative or flat performance metrics.

• · Notes are senior unsecured obligations with interest payable semiannually on June 15 and December 15, starting December 15, 2026.
• · Noteholders may convert at any time prior to March 15, 2031 only upon certain circumstances; after that date, conversion is allowed at any time until the second scheduled trading day before maturity.
• · Upon conversion, Syndax may pay cash, shares of common stock, or a combination, at its election.
• · Syndax cannot redeem the notes before June 20, 2029; after that, redemption is allowed if stock price is at least 130% of conversion price for 20 trading days in a 30-day period.
• · In a fundamental change, noteholders can require Syndax to repurchase notes at 100% of principal plus accrued interest.
• · The notes and any conversion shares are not registered under the Securities Act and cannot be offered or sold in the U.S. without registration or an exemption.

04-06-2026

Genco Shipping & Trading Limited (GNK) sent a letter to shareholders urging them to vote for its board nominees and reject Diana Shipping Inc.'s inadequate $24.80 per share tender offer, which is below Genco's mean analyst NAV estimate of $26.66 and median estimate of $27.10. The company highlights its Comprehensive Value Strategy, which has delivered $7.16 per share in dividends over 27 consecutive quarters, the longest uninterrupted period in the industry. However, Diana's nominees include individuals with records of bankruptcy and shareholder value destruction, and Diana's CEO could personally benefit from a potential acquisition via sale and purchase fees.

• · Genco's annual meeting is scheduled for June 18, 2026.
• · Diana's offer is at a discount to Genco's liquidation value and lacks a control premium.
• · Diana's CEO may receive millions in sale and purchase fees from a potential Genco acquisition via an affiliated entity.
• · Genco's board is majority independent and highly qualified; Diana's nominees include individuals with ties to Diana and records of bankruptcy or shareholder value destruction.
• · Genco's stock price has trended in line with peers since Diana's initial offer, not affected by the offers.
• · Genco is open to meeting with Diana if they submit a proposal reflecting underlying asset value with an appropriate control premium.

04-06-2026

TruBridge, Inc. (TBRG) is being acquired by IKS in an all-cash merger valued at $26.25 per share, representing an 87.5% premium over the unaffected $14.00 closing price on March 30, 2026. The Board unanimously recommends stockholders vote 'FOR' the merger and related executive compensation proposals at a Special Meeting scheduled for July 7, 2026. However, the merger is taxable for U.S. holders, and failure to vote will effectively count as a vote 'AGAINST' the merger proposal.

• · Special Meeting will be held virtually on July 7, 2026 at 8:00 a.m. Central Time.
• · Stockholders of record as of the Record Date must vote; failure to vote has the same effect as a vote 'AGAINST' the merger.
• · The Named Executive Officer Merger-Related Compensation Proposal is non-binding and advisory only; its approval is not required to consummate the merger.
• · Broker non-votes will not be counted for quorum and will have the same effect as a vote 'AGAINST' the merger proposal.
• · Innisfree will be paid a base fee of $20,000 plus a contingent success fee of $10,000 for proxy solicitation.

04-06-2026

NextTrip, Inc. (NTRP) borrowed $200,000 on May 29, 2026 from The Donald P. Monaco Insurance Trust, a related party (director Donald P. Monaco is trustee), as part of a series of short-term unsecured loans. The total principal balance of these Monaco Loans is now $500,000, accruing interest at 7.5% simple interest per annum, with a maturity date of June 30, 2026. The loans were approved by the Board of Directors and Audit Committee, but the short-term nature and reliance on insider funding may signal liquidity constraints.

• · The Monaco Loans commenced on March 25, 2026, and the $200,000 borrowed on May 29 is the latest in that series.
• · The loans are unsecured and mature on June 30, 2026, indicating very short-term financing.
• · The loans were approved by both the Board of Directors and the Audit Committee, suggesting governance oversight of the related-party transaction.

04-06-2026

Janus Detroit Street Trust filed a DEFA14A soliciting material on June 4, 2026, regarding a Joint Special Meeting of Shareholders for Janus Henderson mutual funds/ETFs. The filing includes voicemail and automated phone scripts urging shareholders to vote before the meeting deadline, with a toll-free number (1-855-206-23XX) and extended hours for assistance. No financial data or performance metrics are disclosed in this filing.

• · Filing type is DEFA14A (definitive additional soliciting materials) under SEC Rule 14a-12.
• · Shareholder voting deadline is on an unspecified date in 2026.
• · Shareholders can vote by phone at 1-855-206-23XX, Monday–Friday 9:00 a.m.–10:00 p.m. ET, and weekends 10:00 a.m.–6:00 p.m. ET.
• · The filing includes both a generic voicemail script and an automated phone (PL) script for adjournment reminders.

04-06-2026

Angel Studios, Inc. disclosed in an 8-K filing that, effective May 29, 2026, it began publicly reporting its current active paying Angel Guild member count on its website. The metric is updated regularly, and investors are directed to the company's website for the most current data. No specific member count or financial figures were provided in the filing.

• · The disclosure is made under Item 7.01 (Regulation FD) and is not deemed filed for SEC liability purposes.
• · The company is an emerging growth company as defined under the Securities Act.
• · The company's Class A Common Stock trades on the NYSE under the symbol ANGX.
• · The filing was signed by CFO Scott Klossner on June 4, 2026.

04-06-2026

Denali Therapeutics Inc. held its annual meeting on June 3, 2026, with 86.96% of outstanding shares represented. All three Class III director nominees (Jennifer Cook, David Schenkein, and Ryan Watts) were elected, and stockholders ratified Ernst & Young as the independent auditor for FY2026. Additionally, the advisory vote on executive compensation was approved, though it received notable opposition with 7,088,810 votes against and 717,733 abstentions.

• · The advisory vote on executive compensation received 7,088,810 votes against and 717,733 abstentions, indicating notable shareholder dissent despite approval.
• · Jennifer Cook received the lowest support among director nominees with 75,998,259 votes for and 48,847,029 withheld.
• · Ratification of Ernst & Young as auditor passed overwhelmingly with 137,516,267 votes for and only 420,305 against.

04-06-2026

Gentherm announced its acquisition of Modine's Performance Technologies business via a Reverse Morris Trust, creating a combined company with $2.6B revenue and $320M EBITDA on day one. The deal is expected to close in early Q4 2026. While the core automotive business is expected to grow mid-single digits, the company faces near-term integration risks and the Modine business is coming off a trough in commercial vehicle and off-highway markets.

• · Gentherm expects to double its Medical business to $100M by 2030.
• · The company is consolidating footprint in every region, to be completed by end of 2027.
• · Modine's Performance Technologies business is only 20% light vehicle; other markets include construction, agriculture, mining, commercial vehicle, and power generation.
• · Post-transaction leverage is expected to be just under 1 turn.
• · The transaction is structured as a Reverse Morris Trust with an equity component and distribution.
• · Gentherm realigned organization from regional to functional structure, removing layers of management at director level and above.

04-06-2026

Leggett & Platt, Incorporated announced that the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired for its pending merger with Somnigroup International Inc. However, the transaction remains subject to several other conditions, including shareholder approval, clearance from competition authorities in Canada, the EU, the UK, and the Republic of Korea, and foreign investment approvals in Austria, and is expected to close by year-end 2026.

• · The merger agreement was entered into on April 13, 2026.
• · Remaining conditions include clearance from competition laws in Canada, the European Union, the United Kingdom, and the Republic of Korea, and compliance with foreign investment laws in Austria.
• · A registration statement on Form S-4 must be filed by Parent and become effective with no stop orders.
• · The transaction is subject to the absence of any material adverse effect on either party since the date of the Merger Agreement.

04-06-2026

Avery Dennison announced the appointment of Danny Allouche as President of its Materials Group. Allouche, previously SVP and Chief Strategy and Corporate Development Officer (and interim CFO in late 2024), brings 16 years of internal experience across strategy, M&A, and treasury. The appointment reflects an internal succession but does not disclose separate financial metrics for the Materials Group vs the broader company.

• · Danny Allouche served as interim CFO for a brief period beginning in late 2024.
• · Allouche holds an MBA from UCLA Anderson School of Management and a bachelor’s in economics from Northwestern University.
• · Avery Dennison employs approximately 35,000 employees in more than 50 countries.
• · Reported sales in 2025 were $8.9B.

04-06-2026

Quoin Pharmaceuticals announced that Japan's MHLW granted Orphan Drug Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments. The designation provides development incentives including up to 10 years of market exclusivity upon approval. No financial figures were disclosed.

• · Orphan Drug Designation was granted on March 11, 2026, but announced via press release on June 4, 2026.
• · Netherton Syndrome affects fewer than 50,000 patients in Japan.
• · Incentives include prioritized consultation, reduced fees, tax incentives, priority review, and up to 10 years of market exclusivity.

04-06-2026

Ideal Power Inc. held its 2026 Annual Meeting on June 3, 2026, where stockholders approved all four proposals, including the election of five directors, ratification of BPM LLP as auditor, advisory approval of executive compensation, and the amended 2013 Equity Incentive Plan. The plan was amended to increase authorized shares by 800,000 and extend the term to June 3, 2036. The meeting had a quorum of 57.68% of outstanding shares (7,010,910 shares represented).

• · All five director nominees were elected with 'For' votes ranging from 4,139,174 to 4,273,623; broker non-votes were 2,720,323 for each.
• · Ratification of BPM LLP as auditor passed overwhelmingly with 6,988,321 'For' votes, 14,395 'Against', and 8,194 'Abstain'.
• · Advisory vote on executive compensation (Say-on-Pay) received 3,588,466 'For', 625,041 'Against', and 77,080 'Abstain'.
• · Approval of the amended 2013 Equity Incentive Plan received 3,624,425 'For', 601,975 'Against', and 64,187 'Abstain'.
• · The 2013 Plan term was extended to June 3, 2036.
• · The plan amendment also modified terms relating to repricing, repurchase, or cancellation of options without stockholder approval.

04-06-2026

Hanover Bancorp, Inc. filed an S-4 registration statement to exchange up to $35,000,000 aggregate principal amount of its 7.25% Fixed-to-Floating Rate Subordinated Notes due 2036 (New Notes) for any and all outstanding unregistered 7.25% Fixed-to-Floating Rate Subordinated Notes due 2036 (Old Notes) issued in a private placement on March 12, 2026. The exchange offer is being made to satisfy registration rights obligations and will not generate any cash proceeds or increase outstanding indebtedness. The New Notes are identical in material terms to the Old Notes except for being registered under the Securities Act and not subject to transfer restrictions or additional interest provisions.

• · The exchange offer expires at 11:59 p.m., New York City time, on a date to be specified (noted as [·], 2026).
• · Old Notes not exchanged will remain outstanding; the offer is not subject to any minimum tender condition.
• · There is no existing public market for the Old Notes or New Notes, and no listing on any national securities exchange is intended.
• · Broker-dealers receiving New Notes for their own account must deliver a prospectus for resales for 180 days after the exchange offer completion.
• · The securities are not savings accounts, deposits, or obligations of any bank and are not FDIC-insured.

04-06-2026

Neurogene Inc. held its 2026 Annual Meeting on June 3, 2026, with 11,387,407 shares (72.92% of voting power) present. Stockholders elected Robert Baffi and Rohan Palekar as Class II directors, approved executive compensation on an advisory basis, ratified Deloitte & Touche LLP as auditor for 2026, and voted for annual advisory votes on executive compensation. However, the ratification of Deloitte & Touche LLP received a notable 1,939,039 votes against (17.0% of votes cast), indicating significant shareholder dissent on auditor selection.

• · Record date for the Annual Meeting was April 7, 2026.
• · Robert Baffi received 9,540,734 votes FOR and 548,736 WITHHELD; Rohan Palekar received 10,058,331 FOR and 31,139 WITHHELD.
• · Advisory vote on executive compensation passed with 9,991,445 FOR, 36,394 AGAINST, and 61,631 ABSTAINING.
• · Ratification of Deloitte & Touche LLP as auditor had 9,345,925 FOR, 1,939,039 AGAINST, and 102,443 ABSTAINING.
• · Advisory vote on frequency of future executive compensation votes: 10,006,265 for ONE YEAR, 3,407 for TWO YEARS, 16,721 for THREE YEARS, 63,077 ABSTAINING, and 1,297,937 broker non-votes.
• · The Company will hold future advisory votes on executive compensation annually until the next required frequency vote or Board determination.

04-06-2026

Heritage Global Inc. held its 2026 Annual Meeting of Shareholders on June 3, 2026. Shareholders elected Michael Hexner and William Burnham as Class II directors and ratified UHY LLP as the independent auditor for fiscal year 2026, each with significant majority support.

• · Record date for the Annual Meeting was April 6, 2026.
• · Michael Hexner received 12,393,622 votes for (with 331,369 withheld), and William Burnham received 12,591,056 for (with 133,935 withheld). Both had 10,793,957 broker non-votes.
• · Ratification of UHY LLP received 23,370,993 votes for, 145,179 against, and 2,776 abstentions, with zero broker non-votes.

04-06-2026

Gencor Industries appointed Raymond Cole as Interim Chief Financial Officer, effective June 1, 2026. Mr. Cole brings recent CFO experience at ECD Auto Design (de-SPAC, capital raises, acquisitions) and consulting in specialty sales. He will serve on an at-will basis with a monthly consulting fee of $32,500.

04-06-2026

At Aurinia Pharmaceuticals Inc.'s virtual annual general meeting on June 3, 2026, shareholders elected five directors and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm; director votes were mixed with strong support for Kevin Tang and Kathy Goetz (~96.5% each) but lower support for Craig Johnson and Tina S. Nova (~86.5%-86.9%). The advisory "say on pay" proposal passed with 93.10% For, while the auditor ratification shows 77,785,132 For versus 9,488,350 Withhold (10.86% withheld), indicating overall governance approvals but pockets of relative opposition to certain board nominees and the auditor ratification.

• · Meeting date: June 3, 2026 (virtual annual general meeting).
• · Proposal 1 raw vote counts by nominee (For, Withheld, Broker Non-Votes): Kevin Tang: For 68,889,411; Withheld 2,434,090; Broker Non-Votes 16,049,984.
• · Jeffrey Bailey: For 67,990,723; Withheld 3,332,778; Broker Non-Votes 16,049,984.
• · Kathy Goetz: For 68,840,807; Withheld 2,482,694; Broker Non-Votes 16,049,984.
• · Craig Johnson: For 61,694,786; Withheld 9,628,715; Broker Non-Votes 16,049,984.
• · Tina S. Nova: For 61,972,942; Withheld 9,350,560; Broker Non-Votes 16,049,983.
• · Proposal 2 (auditor ratification) raw counts: For 77,785,132; Withhold 9,488,350; Broker Non-Votes 389.
• · Proposal 3 (say on pay) raw counts: For 66,398,971; Against 4,315,143; Abstain 609,384; Broker Non-Votes 16,049,987.
• · Exhibit filed: 104 Cover Page Interactive Data File (Inline XBRL).
• · Form 8-K filed June 4, 2026; report date (earliest event) June 3, 2026.

04-06-2026

Resideo Technologies, Inc. entered into a Second Amendment and Restatement Agreement on June 4, 2026, to amend its existing credit facility, repay revolving loans, and terminate revolving commitments. The amendment also facilitates the planned spin-off of its ADI global distribution business (expected around August 3, 2026), which will involve a distribution of at least $900 million to Resideo and the release of ADI entities from guarantees and collateral. The company also plans to merge the borrower entity into Resideo Funding II, LLC.

• · The amendment includes both Refinancing Amendments (repaying revolving loans, terminating commitments) and Non-Refinancing Amendments (to permit the ADI spin-off).
• · The ADI Spin-Off Transaction is expected to be completed through a pro rata distribution of all outstanding shares of ADI Global Distribution Inc. to Resideo stockholders.
• · The ADI Spin-Off Entities will be released from guarantees and collateral upon effectiveness of the spin-off, subject to reinstatement if the transaction does not occur.
• · The borrower (Resideo Funding Inc.) plans to merge into Resideo Funding II, LLC, which will become the sole borrower under the amended credit agreement.
• · The amendment also modifies the definition of 'Paid in Full' in the collateral agreement to exclude certain obligations not yet due.

04-06-2026

Royalty Pharma plc held its 2026 Annual General Meeting on June 4, 2026, with 508,180,103 shares (88.08% of voting power) present. All 10 proposals were approved, including the election of nine directors, advisory approval of executive compensation, ratification of Ernst & Young as auditor, and authorization for share allotment and buyback. Notably, director Vlad Coric received the lowest support among nominees with 433,218,530 votes for (88.8% of votes cast), while Elizabeth Weatherman received the highest support with 487,564,658 votes for (99.97%).

• · Proposal 3 (ratify Ernst & Young as auditor) received 506,307,829 votes for, with only 832,217 against and 1,040,057 abstentions.
• · Proposal 10 (authorize allotment of shares without pre-emption rights) had the highest opposition with 42,016,406 votes against (8.6% of votes cast).
• · Broker non-votes totaled 20,320,929 on all proposals except Proposals 3 and 6.
• · The meeting was held on June 4, 2026, and the proxy statement was filed on April 10, 2026.

04-06-2026

Boxabl Inc. announced its first Phase 2 purchase agreement with Shelton Development for 203 boxes (97 homes) in Texas, representing approximately $12.4 million in potential revenue. The agreement adds to a B2B pipeline of over 250 units, while the company works toward completing its business combination with FG Merger II Corp., with the FGMC shareholder meeting scheduled for June 9, 2026. However, the purchase agreement remains subject to conditions and contingencies, and there is no assurance that all units will be delivered or purchased.

• · The purchase agreement is Boxabl's first announced Phase 2 order, expanding beyond the Casita to over 20 housing configurations.
• · Production of the units is expected to begin in approximately 12 months.
• · Boxabl's Phase 2 product offering targets workforce housing, single-family communities, multifamily developments, and other housing applications.
• · The FGMC shareholder meeting to vote on the business combination is scheduled for June 9, 2026.
• · Boxabl was founded in 2017 and its Casita unfolds on-site in less than an hour.
• · The Baby Box is a 120 square foot unit built to RV code for no-foundation setups.
• · Shelton Development has been involved with over 30,000 single-family lots since the late 1960s, focusing mainly on the Dallas-Fort Worth market.
• · The purchase agreement remains subject to conditions, contingencies, and performance requirements; actual deliveries may differ materially.

04-06-2026

NSTS Bancorp, Inc. disclosed that its subsidiary bank, North Shore Trust and Savings, divested its mortgage lending division, Oak Leaf Community Mortgage (OLCM), effective June 1, 2026, as part of the pending merger with Brookfield Bancshares, Inc. The divestiture involved transferring certain assets to an unaffiliated national mortgage lender, with 12 employees leaving the company and four more expected to depart by August 3, 2026. The company does not expect any material gain, loss, or expenses from the divestiture.

• · The OLCM division operated in three locations in the north and western suburbs of Chicago.
• · Transferred assets include certain real estate leases, third party vendor contracts, trademark rights, and other information technology assets.
• · A substantial majority of OLCM employees were hired by the acquiring national mortgage lender.
• · The divestiture is a condition of the merger agreement with Brookfield Bancshares, Inc., signed on May 12, 2026.

04-06-2026

BAB, Inc. held its annual meeting on June 3, 2026, where shareholders elected four directors and ratified the appointment of CBIZ CPAs P.C. as independent auditors for fiscal year 2026. All director nominees received substantial support, with votes for ranging from 2.94M to 2.97M, and the auditor ratification passed with 4.40M votes for, 98k against, and 128k abstentions.

• · All four director nominees were elected with votes for exceeding 2.94 million each.
• · The ratification of CBIZ CPAs P.C. as auditors passed with over 4.4 million votes in favor.
• · Broker non-votes totaled 993,743 for each director election item.
• · No broker non-votes were reported for the auditor ratification proposal.

04-06-2026

Voyager Technologies, Inc. has agreed to acquire 100% of Astrobotic Technology, Inc. in a deal expected to close in the second half of 2026. As partial consideration, Voyager will issue up to an estimated 2,031,694 unregistered shares of Class A common stock as closing shares and additional contingent shares tied to earnout milestones. The shares are issued under Section 4(a)(2) of the Securities Act and are restricted securities.

• · Transaction structure includes both fixed closing shares and contingent earnout shares.
• · Contingent Shares calculation uses 20-trading day VWAP preceding each earnout valuation date.
• · Closing is subject to customary conditions including regulatory approvals; no guarantee of completion.
• · Exact number of Closing Shares depends on final adjustments for cash, indebtedness, option exercises, and transaction expenses.

04-06-2026

Baldwin Insurance Group appointed Johnathan Daniel as interim Chief Accounting Officer effective mid-to-late June 2026 during Corbyn Lichon's maternity leave. At the 2026 Annual Meeting, shareholders elected four Class I directors, approved say-on-pay compensation, and ratified PwC as auditor. No negative or flat metrics were reported.

• · Johnathan Daniel, age 41, has been Executive Director of Finance since January 1, 2026.
• · Daniel previously served as CFO of CAC Group (acquired by Baldwin in Jan 2026) from July 2025 to Dec 2025.
• · Daniel is a CPA and Accredited in Business Valuation.
• · Employment Agreement provides for indefinite term, 120-day notice by Daniel, and standard benefits including open PTO.
• · Annual Meeting voting results: Lowry Baldwin received 94,869,684 For, 4,282,765 Withheld; Sathish Muthukrishnan 98,197,244 For, 955,205 Withheld; Sunita Parasuraman 98,076,188 For, 1,076,261 Withheld; Ellyn Shook 81,501,294 For, 17,651,155 Withheld.
• · Say-on-Pay: 94,240,293 For, 4,125,200 Against, 786,956 Abstain.
• · Ratification of PwC: 109,549,914 For, 62,128 Against, 50,867 Abstain.

04-06-2026

Wesbanco, Inc. announced the retirement of Michael L. Perkins as Senior Executive Vice President and Chief Risk Officer, effective June 30, 2026, and entered into an Executive Transition and Consulting Agreement on June 3, 2026. Under the agreement, Mr. Perkins will serve as a consultant from July 1, 2026, through June 30, 2027, receiving a monthly consulting fee of $33,334, with continued equity vesting conditioned on compliance with a non-competition covenant. The filing does not include any financial results or period-over-period comparisons, so no positive or negative performance metrics are available.

• · Mr. Perkins' retirement was previously announced on January 22, 2026.
• · The consulting period expires on June 30, 2027, unless earlier terminated.
• · The agreement includes a non-competition covenant effective during the consulting term and for one year thereafter.
• · Continued vesting of equity awards is conditioned on compliance with the non-competition covenant.
• · The agreement also includes customary covenants: non-disparagement, cooperation, and return of company property.

04-06-2026

Seneca Bancorp, Inc. announced the retirement of EVP and CFO Vincent Fazio effective June 30, 2026, and the appointment of Angela Krezmer as his successor effective July 1, 2026. The company also appointed Angelo Testani as EVP and Chief Banking Officer, and entered into an amended employment agreement with CEO Joseph Vitale. The changes reflect a leadership transition with new executives receiving base salaries of $220,000 (Krezmer) and $201,375 (Testani), while Fazio will receive a modest $1,000 monthly consulting fee and an increased SERP benefit of $15,000 annually.

• · Angela Krezmer previously served as President, CEO, and CFO of Generations Bank and Generations Bancorp NY, Inc. through their acquisition by ESL Federal Credit Union.
• · Angelo Testani has served as Senior Vice President of Commercial Lending since 2016.
• · The employment agreements for Krezmer and Testani have an initial term through December 31, 2028, with automatic one-year renewals.
• · Severance for change-in-control termination includes three times the sum of base salary and highest annual cash bonus, plus COBRA premium reimbursement for 36 months.
• · Non-competition and non-solicitation restrictions apply for one year after termination (other than following a change in control).
• · CEO Joseph Vitale's amended employment agreement runs through December 31, 2028, with automatic renewals.

04-06-2026

Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting on June 3, 2026, where shareholders ratified KPMG LLP as auditor for fiscal 2026, elected all nine director nominees, and approved a special resolution authorizing a reverse stock split of up to 50:1. The reverse split was approved with strong support (26,729,776 for vs. 2,335,461 against), while director elections saw significant broker non-votes of 13,529,765 for each nominee, indicating potential retail shareholder disengagement.

• · The reverse stock split resolution required a two-thirds supermajority and passed with 26,729,776 votes for (92.0% of votes cast) vs. 2,335,461 against.
• · All nine director nominees received between 15,068,465 and 15,198,014 votes for, with withhold votes ranging from 337,459 to 467,008.
• · Broker non-votes for director elections were 13,529,765 for each nominee, representing approximately 47% of total shares voted on the auditor ratification.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.
• · The company's common shares trade on NASDAQ Capital Market under symbol MDCX, and warrants under MDCXW.

04-06-2026

Nu Ride Inc. (OTC: NRDE) announced an agreement to acquire a majority stake in Affinity Advisory Network, an insurance distribution and wealth advisory platform, for approximately $9.6 million. The transaction includes $6.72 million in cash, 80,000 shares of Class A common stock, and up to $1.312 million in earnout payments, with Affinity's founder retaining a 15% ownership interest. While Affinity generated over $3.5 million in revenue for the 12 months ended March 31, 2026, the acquisition is subject to customary closing conditions and expected to close in Q3 2026, with no guarantee of realizing anticipated benefits.

• · Affinity was founded in 2013 and is headquartered in Ohio.
• · The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.
• · Robert Hall will continue to lead Affinity following the closing.
• · Nu Ride believes there will be multiple organic and inorganic growth opportunities over time.

04-06-2026

Applied Aerospace & Defense, Inc. filed an 8-K on June 4, 2026, announcing the adoption of a Second Amended and Restated Certificate of Incorporation. The amendment includes a 1:1 conversion of Class A and Class B common stock into a single class of Common Stock, followed by a massive 872,901.03-for-1 stock split, and establishes a classified board with three classes of directors. The changes are part of preparations for an initial public offering (IPO).

• · The company was originally incorporated as GB Eagle Topco, Inc. on October 7, 2022.
• · The authorized capital stock consists of 50,000,000 shares of Preferred Stock and 1,000,000,000 shares of Common Stock, each with $0.01 par value.
• · No fractional shares will be issued; fractional shares will be rounded up to the nearest whole share.
• · The Board is authorized to issue Preferred Stock in series with varying rights, which may be superior to Common Stock.
• · The Board is classified into three classes (Class I, II, III) with staggered three-year terms.
• · Before the Trigger Date, directors can be removed with or without cause by a majority vote; after the Trigger Date, removal requires cause and a 66 2/3% vote.
• · The Stockholders Agreement is referenced as governing certain director election and vacancy provisions.

04-06-2026

Abacus Global Management, Inc. held its Annual Meeting on June 3, 2026, where shareholders approved the 2026 Long-Term Equity Incentive Plan, ratified KPMG LLP as independent auditor, and re-elected directors Jay Jackson and Thomas W. Corbett, Jr. as Class III directors. The advisory vote on executive compensation passed, and shareholders selected a one-year frequency for future Say-on-Pay votes. However, the 2026 LTIP and the advisory compensation vote each received over 8 million votes against, indicating notable shareholder dissent.

• · The 2026 LTIP became effective immediately upon shareholder approval on June 3, 2026.
• · The 2026 LTIP is described in Proposal 3 of the Definitive Proxy Statement filed on April 21, 2026.
• · The full text of the 2026 LTIP is filed as Exhibit 10.1 to this Form 8-K.
• · Jay Jackson received 72,107,921 votes FOR and 849,086 WITHHELD; Thomas W. Corbett, Jr. received 67,618,868 FOR and 5,338,139 WITHHELD.
• · Ratification of KPMG LLP passed with 78,073,928 FOR, 33,924 AGAINST, and 65,711 abstentions.
• · Advisory vote on executive compensation passed with 62,263,261 FOR, 8,351,613 AGAINST, and 2,342,133 abstentions.
• · The frequency vote resulted in 52,503,249 FOR 1 year, 54,412 FOR 2 years, and 18,117,425 FOR 3 years, with 2,281,921 abstentions.

04-06-2026

On June 1, 2026, Kathryn Gregory resigned from the Board of Directors of Longevity Health Holdings, Inc., effective immediately. The resignation was not due to any disagreement with the company regarding its operations, policies, or practices.

• · Resignation effective as of close of business on June 1, 2026.
• · No disagreement with the company's operations, policies, or practices was cited.

04-06-2026

Medallion Financial Corp. issued a press release on June 4, 2026, responding to ZimCal's third consecutive proxy contest, accusing Stephen Hodges of pursuing a self-interested debt buyout rather than shareholder value. The company highlights strong long-term performance—net income of $266M over five years, book value per share up 53% since 2021, and a 452% total shareholder return since its transformation—while warning that ZimCal's nominees lack relevant experience, including Eric Kelly's track record of near-total value destruction and pending fraud allegations. However, the filing acknowledges that Q1 2026 results were impacted by a 'growth penalty' from CECL reserves and volatile gains from Medallion Capital, and that Hodges holds only a 2.1% equity stake (0.8% votable) while primarily holding illiquid debt securities.

• · Hodges' debt position pays 6%, below market for similar securities.
• · Hodges proposed a debt-for-equity swap as late as April 13, 2026.
• · In 2024, shareholders rejected ZimCal's nominees by a margin of 3.5 to 1.
• · In 2025, Hodges withdrew his nominees at the last minute.
• · Hodges acquired 99.4% of his shares in 2026.
• · The SEC matter related to conduct from 2014 through 2017 and was settled without admission of wrongdoing.
• · Eric Kelly is defendant in a pending lawsuit scheduled for trial in December 2026, alleging fraud, financial improprieties, and whistleblower retaliation.
• · The SBA declared an event of default on a subsidiary's debentures, described as a technical matter not a financial default.

04-06-2026

Bally's Chicago, Inc. disclosed the appointment of Cheryl Ash as Senior Vice President, Finance and North America and CFO of Bally's Chicago, effective May 29, 2026. Her annual compensation includes a base salary of $350,000, a target bonus of 75% of base salary, and eligibility for future equity grants. No negative or flat performance metrics are present in this filing.

• · Cheryl Ash's employment agreement is with Bally's Management Group, LLC, a subsidiary of Bally's Corporation.
• · The base salary of $350,000 will be reviewed annually.
• · Future equity grants are subject to determination by the compensation committee of Bally's Corporation board of directors.
• · The filing includes a cautionary note regarding forward-looking statements.

04-06-2026

Prudential Financial, Inc. closed the sale of $750,000,000 in aggregate principal amount of its 6.250% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2056 on June 4, 2026. The notes were issued under a supplemental indenture and the offering was underwritten by a syndicate including Wells Fargo, Barclays, Citigroup, Goldman Sachs, and J.P. Morgan. No period-over-period comparisons are available as this is a discrete financing event.

• · The notes are junior subordinated and due in 2056, with a fixed-to-fixed reset rate structure.
• · The underwriting agreement was dated June 1, 2026, and the notes were issued under a Twenty-First Supplemental Indenture dated June 4, 2026.
• · The notes are listed on the New York Stock Exchange under the trading symbol PFH.
• · Legal opinions were provided by Miguel A. Nieves (company counsel) and Willkie Farr & Gallagher LLP (tax counsel).

04-06-2026

DENTSPLY SIRONA Inc. held its annual meeting on June 2, 2026, where all twelve director nominees were elected, and shareholders ratified Deloitte & Touche as the independent auditor for 2026. The non-binding advisory vote on 2025 executive compensation passed with 94.4% support, and Amendment No. 2 to the 2024 Omnibus Incentive Plan was approved, adding 15 million shares. However, director Donald J. Zurbay received significant opposition with 51.1 million votes against (30.4% of votes cast), and the incentive plan amendment saw 27.7 million votes against (16.5% of votes cast), indicating notable shareholder dissent.

• · All director nominees received majority support, but Donald J. Zurbay had the lowest support with 116,568,821 for and 51,059,271 against.
• · Ratification of Deloitte & Touche as independent auditor passed with 182,033,381 for, 465,064 against, and 105,792 abstentions.
• · The non-binding advisory vote on executive compensation had 158,496,058 for, 9,090,084 against, and 255,173 abstentions.
• · Amendment No. 2 to the 2024 Omnibus Incentive Plan was approved with 139,933,388 for, 27,713,777 against, and 194,150 abstentions.
• · Broker non-votes were 14,762,922 for all director elections and the compensation and plan votes, but zero for the auditor ratification.

04-06-2026

BioMarin Pharmaceutical Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, where all ten director nominees were elected and all four proposals were approved, including the ratification of KPMG LLP as independent auditor, an advisory vote on executive compensation, and an amendment to the 2017 Equity Incentive Plan to increase authorized shares by 7,650,000. Notably, director Ian T. Clark received the lowest support with 144,380,101 votes for and 19,160,530 against (11.7% against), while the advisory say-on-pay proposal had 21,287,767 votes against (13.0% of votes cast), indicating notable shareholder dissent on compensation.

• · Director Ian T. Clark received 144,380,101 votes for and 19,160,530 against, the highest number of against votes among all nominees.
• · The advisory say-on-pay proposal had 142,742,800 votes for, 21,287,767 against, and 163,683 abstentions, with 11,619,042 broker non-votes.
• · The Plan Amendment was approved with 158,561,867 votes for, 5,480,380 against, and 152,003 abstentions.
• · KPMG LLP was ratified as independent auditor for fiscal year ending December 31, 2026, with 170,867,335 votes for, 4,850,526 against, and 95,431 abstentions.
• · All director nominees were elected, with the lowest support for Ian T. Clark (144,380,101 for) and the highest for Alexander Hardy (163,115,633 for).

04-06-2026

Hinge Health, Inc. held its 2026 Annual Meeting on June 3, 2026. Stockholders elected Teddie Wardi and Tyler Sloat as Class I directors, with Tyler Sloat receiving overwhelming support (291,330,022 votes for vs. 480,520 withheld) while Teddie Wardi faced a modestly lower approval rate (276,921,911 for vs. 14,888,631 withheld). Stockholders also ratified the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, with nearly unanimous approval (305,789,374 for vs. 121,058 against and 69,093 abstentions). No negative financial or operational metrics were disclosed.

• · Class B common stock holders had 15 votes per share; Series E preferred stock could not vote on director election (Proposal 1).
• · Record date for voting entitlement was April 10, 2026.
• · Proxy statement was filed on April 17, 2026.
• · No broker non-votes occurred on Proposal 2 (auditor ratification).

04-06-2026

Academy Sports & Outdoors held its 2026 Annual Meeting on June 4, 2026, where stockholders elected three Class III directors (Ken Hicks, Beryl Raff, Jeff Tweedy), ratified Deloitte & Touche LLP as auditor for fiscal year ending January 30, 2027, and approved Say-on-Pay on a non-binding advisory basis. All proposals passed with strong support, with Auditor Ratification receiving 59,714,421 votes for (98.3% of votes cast) and Say-on-Pay receiving 56,136,547 votes for (99.0% of votes cast). Additionally, the Board appointed Shannon Hennessy to the Compensation Committee and Clay Johnson to the Audit Committee, effective immediately.

• · All three Class III directors were elected with over 56 million votes for each, and votes withheld were minimal (ranging from 299,837 to 503,348).
• · Broker non-votes were 4,056,313 for each director election and for Say-on-Pay, indicating a significant portion of shares were not voted on these items.
• · Auditor Ratification had 1,025,028 votes against (1.7% of votes cast), the highest opposition among the proposals.
• · Say-on-Pay had 533,746 votes against (0.9% of votes cast) and 45,561 abstentions.
• · The Board appointed Shannon Hennessy to the Compensation Committee and Clay Johnson to the Audit Committee, effective June 4, 2026.

04-06-2026

At the Annual Meeting on June 3, 2026, Abercrombie & Fitch Co. stockholders elected all nine director nominees, approved advisory say-on-pay compensation, and ratified the appointment of PricewaterhouseCoopers LLP as auditor. All proposals passed with strong support, though say-on-pay had 851,288 votes against (2.2% of votes cast).

• · Broker non-votes were 3,024,501 for director elections and say-on-pay, and none for auditor ratification.
• · The highest votes against a director nominee were 559,242 for Kerrii B. Anderson.
• · The meeting was held via remote communication.

04-06-2026

First Guaranty Bancshares, Inc. announced a quarterly cash dividend of $0.01 per share on its common stock, payable on June 30, 2026 to shareholders of record as of June 26, 2026. This marks the 132nd consecutive quarterly dividend paid to common shareholders, demonstrating a long-standing commitment to returning capital to shareholders.

• · Dividend declared on May 21, 2026 by the Board of Directors.
• · Record date: June 26, 2026.
• · Payment date: June 30, 2026.
• · 132nd consecutive quarterly dividend to common shareholders.

04-06-2026

Splash Beverage Group, Inc. sold 3,846,332 shares of common stock to C/M Capital Master Fund, LP from May 29 to June 1, 2026, raising gross proceeds of $607,720 under an existing ELOC Agreement. The sales were made in reliance on exemptions from registration under Section 4(a)(2) and Rule 506(b), with the purchaser's resales registered on a Form S-1 filed in December 2025.

• · The sales occurred under a Securities Purchase Agreement (ELOC Agreement) dated September 19, 2025, previously disclosed in an 8-K filed on September 25, 2025.
• · The purchaser's resales of the shares were registered on Form S-1 (File No. 333-292243) filed with the SEC on December 18, 2025.

04-06-2026

Amerant Bancorp Inc. held its 2026 annual meeting on June 2, 2026, with 69.21% of outstanding shares represented. All 11 director nominees were elected, including Millar Wilson who received significantly lower support (15,336,523 for vs. 8,386,819 against). Shareholders also approved Say-on-Pay and ratified RSM US LLP as auditor for fiscal year 2026.

• · Millar Wilson received 8,386,819 votes against, the highest opposition among all director nominees, with only 15,336,523 for.
• · All other director nominees received over 23 million votes for, with support ranging from 23,099,095 (Gustavo Marturet M.) to 23,684,663 (Carlos Iafigliola).
• · Say-on-Pay was approved with 23,349,064 for, 361,733 against, and 45,915 abstentions.
• · Ratification of RSM US LLP as auditor passed with 27,002,896 for, 17,990 against, and 14,599 abstentions (no broker non-votes).
• · Broker non-votes totaled 3,278,773 on all director elections and Say-on-Pay, but none on auditor ratification.

04-06-2026

Patterson-UTI Energy completed the redemption of all $482.5M of its 3.95% Senior Notes due 2028, funded by proceeds from a new $500M 6.050% Senior Notes due 2036 offering. Stockholders approved an amendment to the 2021 Long-Term Incentive Plan increasing shares by 28.9 million, and ratified PricewaterhouseCoopers as auditor. All ten director nominees were elected, though advisory say-on-pay received 311.5M votes for and 15.6M against, indicating some shareholder dissent.

• · The 2028 Notes were redeemed at 100% of principal plus accrued interest.
• · The new 6.050% Senior Notes due 2036 closed on May 19, 2026.
• · Advisory say-on-pay vote: 311,543,039 for, 15,554,952 against, 193,314 abstentions (broker non-votes 18,069,100).
• · Ratification of PricewaterhouseCoopers: 334,874,711 for, 10,307,536 against, 178,158 abstentions.
• · All ten director nominees received substantial support, with the lowest vote total being Julie J. Robertson at 317,669,255 votes for.
• · The amendment to the 2021 Plan was approved with 319,700,114 votes for, 7,391,767 against, 199,424 abstentions.

04-06-2026

Alphabet announced a massive $80 billion equity capital raise to fund AI infrastructure and compute, including a $10 billion private placement with Berkshire Hathaway. The company reported strong Q1 2026 revenue growth of 22% YoY to $110 billion, with Google Cloud revenue surging 63% YoY and backlog nearly doubling to over $460 billion. However, the massive equity dilution and planned capital expenditure increases to $180-$190 billion in 2026 (with further increases in 2027) signal significant near-term shareholder dilution and execution risk, while the company's debt balance has already exceeded $100 billion.

• · Berkshire Hathaway's investment adds to its position built since Q3 2025.
• · Approximately $30 billion of ATM program proceeds will be used to meet 2026 calendar year tax obligations related to employee equity awards.
• · The mandatory convertible preferred stock will automatically convert after approximately three years (around May 15, 2029) into Class A or Class C stock.
• · Alphabet expects 2027 capital expenditures to significantly increase compared to 2026.
• · The company has raised over $85 billion of debt in the last year across six major currencies, bringing total debt to over $100 billion.
• · Over-allotment options total up to $2.25 billion for stock and $2.25 billion for depositary shares.
• · The depositary shares will be listed on Nasdaq under symbols 'GOOGM' and 'GOOGN'.
• · Capped call transactions are expected to reduce potential dilution from the preferred stock conversion, subject to a cap.
• · The ATM program is not expected to commence until Q3 2026.
• · The underwritten offerings are not conditioned on each other or on the ATM program.

04-06-2026

FingerMotion, Inc. (FNGR) announced on June 4, 2026, that it has agreed in principle with BlueFlare Energy Solutions Inc. to enter into a Memorandum of Understanding (MOU) to develop behind-the-meter (BTM) AI compute infrastructure across Western Canada (Alberta, British Columbia, Saskatchewan). The collaboration aims to build modular, micro-scale AI and HPC compute capacity powered by on-site natural gas, with co-located bitcoin mining serving as a load-balancing mechanism. The MOU is substantially non-binding, with binding exclusivity provisions for FingerMotion only, and the parties aim to negotiate a Commercial Term Sheet for at least one of two initial project sites within 90 days of execution.

• · The exclusivity commitment is non-reciprocal: BlueFlare is not subject to a corresponding exclusivity obligation and may pursue projects with other parties within the Territory.
• · The MOU is substantially non-binding; only exclusivity, anti-circumvention, confidentiality, public-disclosure, governing-law and dispute-resolution provisions are intended to be binding.
• · The 90-day milestone for a Commercial Term Sheet is aspirational and non-binding; failure to meet it would not constitute a breach.
• · FingerMotion's strategy is to treat bitcoin mining as a load-balancing and asset-utilization mechanism, not a primary use case.

04-06-2026

ArcBest provided a preliminary business update for Q2 2026, reporting mixed performance across segments. In the Asset-Based segment, May billed revenue per day grew 9% YoY and tonnage per day rose 5%, but shipments per day declined 4% YoY. The Asset-Light segment showed stronger growth with May daily revenue up 32% YoY, though purchased transportation expense remained high at 87% of revenue. The company expects Q2 Asset-Based non-GAAP operating ratio to improve by 600-700 basis points sequentially, while Asset-Light non-GAAP operating income is forecasted at $3M-$5M.

• · Asset-Based revenue per hundredweight excluding fuel surcharge was flat YoY in May 2026.
• · Sequentially from April to May 2026, Asset-Based weight per shipment increased 5%, shipments per day decreased 1%, and tonnage per day increased 4%.
• · Asset-Light sequentially from April to May 2026: daily revenue up 7%, daily shipments down 2%, revenue per shipment up 9%.
• · Asset-Light purchased transportation expense as a percentage of revenue was 87% in May 2026, up from 86.2% in April 2026.
• · The company expects Q2 2026 Asset-Based non-GAAP operating ratio to improve by 600-700 basis points sequentially, compared to the historical average improvement of approximately 350 basis points from Q1 to Q2.

04-06-2026

On June 3, 2026, Jade Biosciences, Inc. (JBIO) entered into an underwriting agreement to sell 10,000,000 shares of common stock at $15.00 per share, with an underwriter option for up to 1,500,000 additional shares. Net proceeds are expected to be approximately $140.3 million, or $161.5 million if the option is fully exercised. The offering is expected to close on June 5, 2026, utilizing the company's existing shelf registration statement; proceeds will be used for general corporate purposes.

• · Offering is being made under shelf registration statement Form S-3 (No. 333-295662)
• · Underwriters' discount is $0.90 per share ($15.00 - $14.10)
• · Underwriting Agreement includes customary representations, warranties, indemnification, and termination provisions
• · Company is an emerging growth company and has elected not to use extended transition period for new accounting standards
• · Legal opinion on share validity provided by Brownstein Hyatt Farber Schreck, LLP (Exhibit 5.1)